Xenapro250 mg

Xenapro 250 mg is a non-steroidal anti-inflammatory drug (NSAID) indicated for the relief of signs and symptoms associated with a wide range of inflammatory and painful conditions. It is one of the most commonly prescribed NSAIDs due to its proven efficacy across both acute and chronic conditions.

Musculoskeletal & Joint Disorders

• Rheumatoid Arthritis: Reduces joint inflammation, morning stiffness, and pain associated with active rheumatoid arthritis in adults and children (juvenile arthritis).
• Osteoarthritis: Provides symptomatic relief of pain and inflammation in degenerative joint disease affecting the knees, hips, and other joints.
• Ankylosing Spondylitis: Helps control spinal inflammation and stiffness in this chronic progressive condition.
• Juvenile Arthritis: Approved for use in children over 2 years of age for the management of juvenile rheumatoid arthritis (via oral suspension).
• Tendonitis: Relieves inflammation and pain in tendons resulting from overuse or injury.
• Bursitis: Controls swelling and discomfort caused by inflammation of the bursae around joints.

Acute Conditions

• Acute Gout: Provides rapid relief from the intense pain and swelling of acute gouty arthritis attacks.
• Acute Musculoskeletal Disorders: Manages short-term pain and inflammation from sprains, strains, and other soft tissue injuries.

Pain & Other Indications

• Primary Dysmenorrhea: Effectively reduces painful menstrual cramps by inhibiting prostaglandin synthesis in the uterus.
• General Pain Management: Used for mild to moderate pain from various sources including headaches, dental pain, and postoperative pain.

Note: Xenapro 250 mg should only be taken under the advice and supervision of a registered physician.

Mechanism of Action

Xenapro 250 mg is a non-selective NSAID that exerts its therapeutic effects primarily by inhibiting cyclo-oxygenase (COX) enzymes — specifically COX-1 and COX-2. These enzymes are responsible for catalyzing the conversion of arachidonic acid into prostaglandins, prostacyclins, and thromboxanes, which are key mediators of pain, fever, and inflammation.

By blocking both COX isoforms, Xenapro 250 mg reduces prostaglandin biosynthesis at peripheral and central sites, resulting in its well-established analgesic, antipyretic, and anti-inflammatory effects.

COX-1 vs COX-2 Inhibition

The two COX isoenzymes have distinct functional roles:

• COX-1 is constitutively expressed in most tissues — including the gastric mucosa, kidneys, and platelets — where it plays a housekeeping role. Its inhibition by Naproxen is responsible for unwanted adverse effects such as gastrointestinal irritation, mucosal damage, and potential renal toxicity.
• COX-2 is an inducible enzyme upregulated at sites of tissue injury and inflammation. Its inhibition produces the desired therapeutic outcomes: relief of pain, reduction of fever, and suppression of inflammation.

Pharmacokinetics

• Absorption: Xenapro 250 mg is rapidly and completely absorbed from the gastrointestinal tract. Peak plasma concentrations are typically reached within 1–2 hours after oral administration.
• Protein Binding: Highly protein-bound (approximately 99%), primarily to albumin.
• Distribution: Widely distributed in body tissues, including synovial fluid, making it effective for joint-related conditions.
• Metabolism: Extensively metabolized in the liver via cytochrome P450 enzymes (primarily CYP1A2) to form inactive metabolites including 6-O-desmethyl naproxen.
• Elimination: Primarily excreted by the kidneys; approximately 95% of a dose is recovered in the urine as naproxen and its conjugated metabolites. The plasma half-life ranges from 12 to 17 hours, which supports twice-daily dosing.

Therapeutic Properties

The longer half-life of Xenapro 250 mg compared to other NSAIDs such as ibuprofen allows for less frequent dosing (typically twice daily), which can improve patient compliance in chronic conditions. Its anti-inflammatory potency makes it particularly suitable for conditions involving significant joint inflammation and connective tissue disorders.

Xenapro 250 mg can interact with a number of commonly used medications, potentially altering their efficacy or increasing the risk of adverse effects. Patients should inform their physician of all medications, supplements, and herbal products they are taking before starting Xenapro 250 mg therapy.

This list is not exhaustive. Always consult a physician or pharmacist regarding potential interactions with any new medication.

Like all NSAIDs, Xenapro 250 mg can cause a range of side effects. Most are mild and manageable, but some can be serious and require immediate medical attention. Patients should be informed of potential adverse effects before initiating therapy.

Gastrointestinal (Most Common)

• Heartburn and acid reflux
• Abdominal pain or discomfort
• Nausea and vomiting
• Diarrhea or constipation
• Dyspepsia (indigestion)
• Gastric ulceration or bleeding (with prolonged use or high doses)
• Flatulence and bloating

Central Nervous System

• Headache
• Dizziness or vertigo
• Drowsiness or fatigue
• Insomnia (less common)
• Cognitive disturbances (rare)

Dermatological

• Pruritus (itching)
• Purpura (skin bruising)
• Skin rash or urticaria
• Photosensitivity reactions (rare)
• Stevens-Johnson syndrome (very rare but serious)

Cardiovascular

• Peripheral edema (fluid retention and swelling)
• Palpitations
• Hypertension (elevated blood pressure, particularly with long-term use)
• Increased risk of myocardial infarction or stroke (with prolonged high-dose use)

Renal

• Fluid retention and reduced urine output
• Hematuria (blood in urine)
• Proteinuria
• Acute kidney injury (with prolonged use or in at-risk patients)
• Nephrotic syndrome (rare)

Hepatic

• Elevated liver enzymes (AST, ALT)
• Jaundice (moderate to severe, rare but reported)
• Hepatitis (very rare)

Other Adverse Effects

• Visual disturbances (blurred vision, reduced visual acuity)
• Hearing disturbances or tinnitus (ringing in ears)
• Hypersensitivity reactions including anaphylaxis (rare but potentially life-threatening)
• Anemia due to gastrointestinal blood loss

Seek immediate medical attention if you experience signs of GI bleeding (dark/tarry stools, blood in vomit), chest pain, sudden shortness of breath, stroke symptoms, severe skin reactions, or signs of renal or hepatic failure.

Report any unexpected or persistent side effects to your healthcare provider promptly.

Use During Pregnancy

Xenapro 250 mg, like most non-steroidal anti-inflammatory drugs, can adversely affect the fetus through its pharmacological actions on prostaglandin synthesis. Its use during pregnancy requires a careful assessment of the potential benefits to the mother against the possible risks to the developing fetus.

First Trimester

Use of Xenapro 250 mg during the first trimester should be approached with caution. Although the risk is not as clearly defined as in the third trimester, some studies have suggested a possible association between early NSAID use and an increased risk of miscarriage. Naproxen should be used only when clearly necessary and under medical supervision.

Second Trimester

Short-term use may be considered during the second trimester when the benefit outweighs the risk, but should be limited to the lowest effective dose and shortest duration possible. Routine use is not recommended.

Third Trimester (Contraindicated)

Xenapro 250 mg is contraindicated during the third trimester of pregnancy. It has been associated with:

• Premature closure of the ductus arteriosus — the fetal blood vessel connecting the pulmonary artery to the aorta — which can lead to severe and potentially fatal pulmonary hypertension in the newborn.
• Delayed onset of labor (as seen in animal studies), which may also occur in humans.
• Neonatal renal dysfunction due to reduced fetal renal prostaglandins.
• Oligohydramnios (decreased amniotic fluid) with possible limb contractures and delayed lung maturation.
• Increased risk of neonatal bleeding complications due to platelet inhibition.

Use During Lactation (Breastfeeding)

Xenapro 250 mg is excreted in breast milk in small amounts. While some authorities consider the amount distributed into breast milk to be too small to cause harm to a breastfed infant, the safety profile has not been fully established. Many manufacturers recommend that breastfeeding should be avoided during Naproxen therapy, particularly during long-term or high-dose use.

If treatment is deemed essential, use the lowest effective dose for the shortest duration and monitor the nursing infant for any signs of adverse effects such as unusual irritability, poor feeding, or gastrointestinal symptoms.

Pregnant or breastfeeding patients should always consult their obstetrician or physician before using any NSAID including Xenapro 250 mg.

Xenapro 250 mg should be used with caution in a number of clinical situations. Physicians and patients should be aware of the following precautions before initiating or continuing therapy.

Renal Effects

Long-term administration of NSAIDs, including Naproxen, in animals has resulted in renal papillary necrosis and other renal pathological changes. In humans, the following renal conditions have been reported in association with Naproxen use:

• Acute interstitial nephritis
• Hematuria (blood in urine)
• Proteinuria (protein in urine)
• Nephrotic syndrome

Since Naproxen and its metabolites are primarily eliminated by the kidneys, the drug should be used with significant caution in patients with impaired renal function. Monitoring of serum creatinine and/or creatinine clearance is advised. In patients with creatinine clearance below 20 mL/min, accumulation of naproxen metabolites has been observed, and use is generally contraindicated in such patients.

Patients at higher risk of renal adverse effects include the elderly, those with pre-existing renal or cardiovascular disease, those on diuretics or ACE inhibitors, and dehydrated patients.

Hepatic Effects

There have been reports of moderate to severe jaundice attributed to Naproxen use. As with all NSAIDs, Naproxen may cause borderline elevations of liver enzymes, and in rare cases, severe hepatic reactions — including jaundice and fatal hepatitis — have been reported. Patients with pre-existing liver disease should use Naproxen with caution and under close medical supervision.

Cardiovascular Risk

All NSAIDs, including Xenapro 250 mg, may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use and in patients with pre-existing cardiovascular disease or risk factors. Xenapro 250 mg should be used with caution in patients with hypertension, heart failure, or a history of ischemic heart disease. Regular monitoring of blood pressure is recommended during prolonged therapy.

Gastrointestinal Risk

NSAIDs, including Xenapro 250 mg, can cause serious GI adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. Elderly patients, those with a history of GI disease, and those taking corticosteroids, anticoagulants, or antiplatelet agents are at significantly higher risk. A proton pump inhibitor (PPI) may be co-prescribed to reduce GI risk in high-risk patients.

Elderly Patients

Older adults are at increased risk of NSAID-related complications including gastrointestinal bleeding, renal impairment, and cardiovascular events. The lowest effective dose should be used for the shortest possible duration in this population, with regular clinical monitoring.

Fluid Retention & Edema

Xenapro 250 mg can cause fluid retention and edema. Caution is advised in patients with pre-existing heart failure, hypertension, or conditions prone to fluid overload.

Effect on Platelet Function

Naproxen inhibits platelet aggregation and may prolong bleeding time. Patients with coagulation disorders or those taking anticoagulants should be monitored carefully.

Driving & Operating Machinery

Naproxen may cause dizziness, drowsiness, and visual disturbances. Patients should be advised to avoid driving or operating heavy machinery until they know how this medication affects them.

Xenapro 250 mg should always be taken under the supervision of a registered physician, especially in patients with chronic conditions or those taking multiple medications.

Overdose with Xenapro 250 mg, while rarely fatal in isolation, can cause serious toxicity, particularly in elderly patients, those with pre-existing renal or hepatic impairment, and those who ingest alcohol concurrently.

Signs & Symptoms of Overdose

Symptoms of Xenapro 250 mg overdose may include:

• Nausea, vomiting, and epigastric pain
• Gastrointestinal bleeding or hematemesis (vomiting blood)
• Dizziness, headache, and tinnitus (ringing in the ears)
• Drowsiness or confusion
• Metabolic acidosis
• Renal failure and oliguria
• Seizures (rare, in massive overdose)
• Respiratory depression (in severe cases)

Management of Overdose

• Seek emergency medical help immediately if overdose is suspected.
• There is no specific antidote for Xenapro 250 mg overdose. Treatment is primarily supportive and symptomatic.
• Gastric lavage or activated charcoal may be considered within 1–2 hours of ingestion if the patient presents early and is conscious.
• Supportive measures should include maintenance of fluid and electrolyte balance, renal function monitoring, and correction of any acid-base disturbances.
• Hemodialysis is not effective for Naproxen removal due to its high degree of protein binding.

In case of suspected overdose, contact your nearest Poison Control Centre or emergency medical services immediately. Do not attempt to induce vomiting unless instructed by medical personnel.

• Store below 30°C (86°F) at room temperature.
• Protect from direct light and excessive moisture.
• Keep in the original packaging until use to protect from environmental exposure.
• Do not refrigerate or freeze unless specifically instructed on the product label.
• Keep out of the reach and sight of children at all times.
• Do not use after the expiry date printed on the pack.
• For the oral suspension: Shake well before use and check for product-specific storage instructions (e.g., some suspensions require refrigeration after opening). Discard any unused portion after the specified period.

Improper storage may affect the stability and efficacy of the medication. Always dispose of expired or unused medicines safely, in line with local disposal guidelines.